HB 1139

  • North Dakota House Bill
  • 67th Legislative Assembly (2021-2022)
  • Introduced in House Apr 05, 2021
  • Passed House Jan 27, 2021
  • Passed Senate Mar 23, 2021
  • Signed by Governor Apr 01, 2021

Relating to duration limits for opioid therapy and benzodiazepine; and to provide for application.

Votes


No votes to display

Actions


Apr 05, 2021

North Dakota Legislative Assembly

Filed with Secretary Of State 04/01

Apr 01, 2021

Office of the Governor

Signed by Governor 03/31

Mar 29, 2021

Office of the Governor

Sent to Governor

House

Signed by Speaker

Mar 25, 2021

Senate

Signed by President

Mar 24, 2021

House

Returned to House

Mar 23, 2021

Senate

Second reading, passed, yeas 38 nays 8

Mar 22, 2021

Senate

Reported back, do pass, place on calendar 5 1 0

Mar 08, 2021

Senate

Committee Hearing 02:30

Feb 15, 2021

Senate

Introduced, first reading, referred Industry, Business and Labor Committee

Jan 28, 2021

Senate

Received from House

Jan 27, 2021

House

Second reading, passed, yeas 64 nays 26

Jan 21, 2021

House

Reported back, do pass, place on calendar 12 1 1

Jan 18, 2021

House

Committee Hearing 08:00

Jan 08, 2021

House

Introduced, first reading, referred Industry, Business and Labor Committee

Bill Text

Bill Text Versions Format
INTRODUCED PDF
Enrollment PDF

Related Documents

Document Format
INTRODUCED PDF

Sources

Data on Open States is updated periodically throughout the day from the official website of the North Dakota Legislative Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.